| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2116383 | Cancer Letters | 2011 | 8 Pages |
HER-2/neu over-expression occurs in 10–40% of patients with esophageal adenocarcinoma. Therefore, inhibitory effects of trastuzumab on proliferation, neoangiogenesis and metastatic spread of the esophageal adenocarcinoma cell line PT1590 were investigated (subcutaneous xenograft model). PT1590 revealed an amplified copy number of c-erbB2 and HER-2/neu over-expression occured in xenograft tumors and spontaneous lung metastases. PT1590 proliferation was significantly inhibited by trastuzumab in vitro. In vivo, tumor weight, volume, microvessel density and number of lung metastases decreased significantly after three weeks of treatment. These data suggest the importance of HER-2/neu for metastatic spread in esophageal adenocarcinoma and encourages clinical trials.
► Trastuzumab is anti-proliferative in HER-2/neu expressing esophageal adenocarcinoma. ► Trastuzumab reduces tumor growth of esophageal adenocarcinoma xenograft model. ► Trastuzumab reduces metastasis formation. ► Trastuzumab reduces tumor angiogenesis.
